Skip to main content
Premium Trial:

Request an Annual Quote

New Products: OGT's RNA-Seq Services; Agilent's SureDesign; and More


Oxford Gene Technology has launched the Genefficiency RNA Sequencing service. The service is customizable, and includes a consultation with a bioinformatician after the data report is delivered.

Agilent Technologies has introduced SureDesign, an online interface to help researchers create customized target enrichment panels for next-generation sequencing. The interface is compatible with all of Agilent's target-enrichment formats, including the HaloPlex and SureSelect systems.

Researchers from the University of Maryland and the Massachusetts Institute of Technology have released TopHat 2.0.5 and CummeRbund 2.0.0, respectively. The TopHat release, available here, includes new options to control the read alignment
and to improve mapping accuracy, as well as the ability to resume partial runs.

The CummeRbund release, available here, offers new options and features, fixes bugs, and fully supports Cuffdiff2.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.